Publication date: Aug 10, 2019
SALT LAKE CITY, Aug. 09, 2019 (GLOBE NEWSWIRE) — Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent clinical intervention through precision therapies, announces that its wholly owned subsidiary Predictive Laboratories, Inc. has commercially launched PGxPLUS+, a pharmacogenomic test panel being marketed to pain clinics for patients with chronic pain.
In parallel, Predictive Laboratories has reached a milestone of enrolling 350 patients with chronic pain into an Investigational Review Board-approved clinical study aimed at providing additional insight into the mechanisms of chronic pain and responses to pain therapies.
Predictive has already developed and in-licensed important prognostic DNA tests and novel treatments for osteoarthritis, lumbar disc disease, endometriosis, and other conditions causing chronic pain.
Predictive’s test evaluates 112 genetic variants across 38 genes that affect the metabolism of over 150 common medications, including pain medications.
In the clinical study, Predictive is testing patients who are taking high doses of opioids [≥50 morphine milligram equivalents (MME)/day] for genetic variants responsible for their underlying disease, their metabolism of opioids, their intrinsic pain thresholds, and any genetic predisposition to opioid addiction.
We are pleased to add the PGxPLUS+ test to our portfolio of regenerative medicine and diagnostic products focused on treating chronic pain diseases. “
|disease||DOID||degenerative disc disease|
- CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.
- The Endogenous Opioid System and Mindfulness